SCA
ATRA icon

Secor Capital Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Secor Capital Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,211
Closed -$424K – 433
2017
Q2 		$424K Buy
+1,211
New +$467K 0.04% 363
2016
Q1 		– Sell
-491
Closed -$324K – 606
2015
Q4 		$324K Buy
+491
New +$371K 0.09% 349

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Secor Capital Advisors's ATRA Position: Q3 2017 in Review

Secor Capital Advisors sold out of Atara Biotherapeutics (ATRA) in Q3 2017, closing a stake of 1,211 shares — an estimated $424K sold.

Secor Capital Advisors first reported a position in ATRA in Q4 2015 and held it in 2 quarters. The position peaked at $424K in Q2 2017. 82 funds tracked by Wall St. Rank hold ATRA as of Q3 2017.

  • Secor Capital Advisors reported no remaining Atara Biotherapeutics position as of Q3 2017 after selling out during the quarter.
  • Secor Capital Advisors sold 1,211 Atara Biotherapeutics shares in Q3 2017, an estimated $424K.
  • Secor Capital Advisors first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 2 quarters.
  • Secor Capital Advisors's Atara Biotherapeutics position peaked at $424K in Q2 2017.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2017.

Based on Secor Capital Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.